New platform reinforces Infobip’s shift to AI-first customer experience in its 20th year

KUALA LUMPUR, Malaysia, March 2, 2026 /PRNewswire/ — Global AI-first cloud communications platform Infobip, which celebrates its 20^th anniversary this year, is set to launch its AI-native fully managed solution AgentOS. The new platform builds on Infobip’s recently launched AI Agents, the intelligent foundation for autonomous customer communications. AgentOS is a major step in Infobip’s evolution from communications platform to intelligent orchestration layer for the AI era, enabling businesses to move from campaigns and workflows to autonomous, goal-driven interactions.

AI communication models enable autonomous customer communications, hyper-personalization and highly engaging content across multiple channels. However, AI agents need a unified view of all customer touchpoints to deliver such benefits. Businesses must eliminate data silos. Yet readiness is low. Few enterprise AI agent projects reach production due to unstructured data and internal barriers. AgentOS overcomes these barriers, operationalizing AI safely and at scale across the enterprise.

AgentOS combines Infobip’s Conversational Customer Data Platform with real-time journey orchestration to deliver one and two-way contextual engagement across all natively integrated channels. The platform unites marketing, sales and support into one AI-native platform to connect every customer touchpoint into a seamless journey. This means fewer disconnected tools, faster execution and measurable improvements in customer conversion, satisfaction and lifetime value.

Infobip’s real advantage lies in its human-in-the-loop model, where AI manages scalability and efficiency, and human specialists intervene to address complex issues, continuously training and refining the AI agents. Retailers and eCommerce companies are at the forefront, delivering hyper-personalized experiences, while healthcare and finance sectors are quickly embracing AI-powered solutions to improve patient care with a strong focus on trust, security, and regulatory compliance.

Moreover, modular components, MCP interfaces, open APIs, and intuitive user interface elements enable fast deployment, integration or standalone use. Brands can start with one use case, enhance customer experience and scale to other use cases quickly. Built-in security and compliance ensure every interaction is trusted, giving enterprises the confidence to automate without losing control. Automation and analytics power hyper-personalized engagement and operational efficiency at scale.

Krešo Žmak, Chief Innovation Officer at Infobip, said: “AgentOS is the control layer where AI agents, data, channels and customer intent come together to decide what happens next in every interaction. It leverages our omnichannel foundation to enable AI agents to operate autonomously across SMS, RCS, email, WhatsApp, voice, and more, adapting in real-time to optimize content, channel and timing based on customer context. With more than 15 natively integrated channels, Infobip is uniquely positioned to deliver agentic AI at scale.”

Infobip has integrated Model Context Protocol (MCP) servers into its platform to provide AI agents with communication superpowers. By creating a universal language where AI agents can interact with third-party systems, Infobip’s MCP servers enable AI agents to book flights, set up two-factor identification and more. No matter if a brand uses an Infobip or third-party agent, they can make the most of Infobip’s global omnichannel communications platform to complete real AI-first customer tasks end-to-end.

AgentOS is available directly from Infobip on 1 April. More about AI agents here: https://www.infobip.com/ai-agents

About Infobip (Infobip Asia Pacific Sdn Bhd Company No: 201001014145/898379-U)

Infobip is a global cloud communications platform that enables businesses to build connected experiences across all stages of the customer journey, with AI as the driving force of innovation. Through a single, natively built platform, Infobip delivers omnichannel engagement, identity, user authentication and contact centre solutions that help businesses and partners overcome the complexity of consumer communications while driving growth and increasing customer loyalty. Infobip is focused on enabling and accelerating AI adoption as it continues its transformation into an AI-first company. Infobip’s technology has the capacity to reach over seven billion mobile devices in 6 continents connected to over 10k+ connections of which 800+ are direct operator connections. The company was established in 2006 and is led by its co-founders, CEO Silvio Kutić and Izabel Jelenić.

–       Seizing the golden time for a major transformation, with ‘Customer Value & AI’ as the top two priorities for driving change

–       Major overhaul of systems and infrastructure, the foundation of telecommunications, centered on AI

–       Redesigning customer-friendly products, promoting integrated AI agents, and strengthening communication with customers

–       Advancing hyperscale AI data centers, developing 1000B AI models, and focusing on manufacturing AI to help Korea become one of the world’s top three AI leaders

BARCELONA, March 2, 2026 /PRNewswire/ — SK Telecom (NYSE:SKM, hereinafter referred to as “SKT”) has announced a major transformation to lead the era of AI.

On March 1, SKT CEO Jung Jai-hun held a press conference in Barcelona, Spain, and announced the company’s ‘AI Native’ innovation strategy, which includes a reorganization of AI infrastructure and large-scale investment plans.

This strategy reflects SKT’s ambition to redesign its telecommunications leadership DNA into an AI-driven DNA, building on its core strengths, and to lead Korea’s leap toward becoming one of the world’s top three AI leaders through bold challenges and change. 

CEO Jung Jai-hun stated, “SKT is currently at a golden time of transformation, where the two tasks of ‘customer value innovation’ and ‘AI innovation’ intersect in a borderless, converged environment that goes beyond telecommunications. SKT defines ‘the customer as the very essence of our business,’ and through innovation driven by AI, we will evolve into a company that makes meaningful contributions to our customers and to Korea.”

• Maximizing Customer Value with ‘AI-powered Telco‘ 

SKT plans to build stronger relationships with customers and significantly enhance customer-perceived value by applying AI across all areas of telecommunications.

To achieve this, SKT will undertake a major overhaul of its integrated IT systems, the foundation of its telecom services, redesigning them to be optimized for AI.

SKT will build all integrated systems, including sales IT, line management, and billing systems, around AI, enabling the company to promptly design and provide personalized plans and memberships tailored to each customer’s needs.

In particular, SKT will establish a Zero Trust information security framework across all systems, strengthening security through rigorous authentication, access control, network segmentation, and AI-based integrated security monitoring.

SKT is also accelerating its ‘autonomous network operations’ strategy, which leverages AI to automate network management.

SKT is set to transition from human-centered operations to AI-driven autonomous systems across wireless quality management, traffic control, and network equipment and facility operations, with the goal of maximizing customer-perceived quality. With AI-RAN technology, the company plans to deliver ultra-fast, seamless, and ultra-low latency communications.

• Customer-Friendly Redesign Across All Touchpoints, from Services to Customer Touchpoints—Enhancing Two-Way Communication with Customers

SKT plans to redesign its telecom services and products to be more customer-friendly, while also strengthening two-way communication with customers.

For services such as pricing, roaming, and membership, SKT will prioritize customer convenience by restructuring them into simple and intuitive formats and automatically offering personalized packages.

SKT is also developing an ‘integrated AI agent’ that connects the dispersed customer experiences across various touchpoints, such as T world (SKT’s main customer portal) and T Direct Shop (SKT’s official online store).

By quickly analyzing customers’ daily patterns and needs with AI, SKT aims to create a single agent that delivers personalized experiences at every touchpoint. In addition, SKT will enhance its AI Contact Center (AICC), enabling all customer service representatives to use AI for accurate and prompt support.

Offline stores will also leverage AI to shift from sales-focused operations to providing deeper customer experiences, accurately identifying needs, and automatically offering personalized recommendations even after a visit—delivering highly tailored curation services. 

In addition, SKT plans to create ‘AI Personas’ to analyze digital behavior data across various customer segments, enabling a comprehensive understanding of each customer’s needs and preferences through natural, conversational Q&A. This approach will allow SKT to communicate more effectively with all customers.

SKT is further advancing ‘A. phone (A-DoT phone),’ developing it into a true AI agent that can automatically organize call notes and schedules, connect customers to personalized services, and even perform related actions. 

SKT plans to expand opportunities for employees to engage directly with customers in the field, fostering two-way communication. This year, SKT plans to actively listen to a wide range of customer groups, as well as experts from industry and academia, and thoroughly reflect their voices in all aspects of company management.

• Building 1GW-Class AI Data Centers Nationwide to Establish Asia‘s Largest AIDC Hub

SKT will build 1GW-class hyperscale AI data center (AIDC) infrastructure across Korea, aiming to attract global investment and establish the nation as Asia’s largest AIDC hub.

In addition to its GPU cluster Haein, SKT is building AIDCs and plans to expand to hyperscale capacity exceeding 1GW through global partnerships. The company also plans to build an AIDC in Korea’s southwestern region in collaboration with OpenAI, as part of its broader vision to establish a nationwide AI infrastructure network.

Together with SK hynix, SK Ecoplant, and SK Innovation, SKT will secure solutions across the entire value chain—from AIDC construction to cooling, servers, energy, and operations—to provide AIDCs with industry-leading cost efficiency.

Last year, SKT applied its high-performance, high-efficiency virtualization solution ‘Petasus AI Cloud’ to Haein, its GPU cluster built for GPUaaS, and this year plans to offer Petasus AI Cloud in the global market.

SKT will upgrade its sovereign AI foundation model, currently the largest in Korea at 519B parameters, to over 1T (one trillion parameters), securing AI sovereignty and driving innovation across industries. In particular, SKT plans to enhance the model by adding multimodal capabilities, enabling it to process not only image data but also voice and video data, starting in the second half of this year.

Moreover, SKT will focus on jointly developing a ‘manufacturing-specialized AI solution’ package with SK hynix to strengthen the competitiveness of Korea’s manufacturing industries, including semiconductors and energy. This package analyzes process data in real time to reduce defect rates and maximize equipment efficiency, and will be offered in three forms: infrastructure, model, and solution.

CEO Jung stated, “AIDC can be seen as the heart of Korea, and hyperscale LLMs as the brain. By combining SKT’s AI capabilities with collaboration from domestic and global partners, we will lead true AI-native transformation for Korean customers and enterprises.”

• Transforming Work Culture Around AI

CEO Jung emphasized, “To drive future growth, we must reinvent our way of working from the ground up. SKT will fundamentally transform its corporate culture to be centered around AI.”

SKT has built an ‘AX (AI Transformation) Dashboard’ that provides a comprehensive view of AI utilization by department and individual, accelerating AI adoption across the organization. In addition, SKT operates an ‘AI Board’ to strengthen dedicated support for AX initiatives and is fostering a work environment and culture where employees can naturally incorporate AI into their daily tasks.

SKT has also built an ‘AI playground,’ enabling employees to easily develop and use AI agents for their work without coding. Currently, more than 2,000 AI agents are being actively used across areas such as marketing, legal, and PR.

CEO Jung stated, “By implementing company-wide AI upskilling education and campaigns, we will transform our organizational culture to be AI Native. Through SKT’s new transformation, we will do our utmost to regain the trust of our customers and become a company that contributes to the nation and society.”

About SK Telecom

SK Telecom has been leading the growth of the mobile industry since 1984. Now, it is taking customer experience to new heights by extending beyond connectivity. By placing AI at the core of its business, SK Telecom is rapidly transforming into an AI company with a strong global presence. It is focusing on driving innovations in areas of AI Infrastructure, AI Transformation (AIX) and AI Service to deliver greater value for industry, society, and life.

For more information, please contact skt_press@sk.com or visit our LinkedIn page www.linkedin.com/company/sk-telecom.

– XPOVIO^® is the first XPO1 inhibitor approved for reimbursement by South Korea’s National Health Insurance Service (NHIS) for the treatment of adult patients with multiple myeloma (MM).

– In South Korea, XPOVIO^® has been approved for three indications across MM and diffuse large B-cell lymphoma (DLBCL), and two of these approved indications have been included in the national reimbursement scheme.

SHANGHAI and HONG KONG, March 2, 2026 /PRNewswire/ — Antengene Corporation Limited  (“Antengene”, SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies indications, announced that South Korea’s National Health Insurance Service (NHIS) has approved the reimbursement of XPOVIO^® (selinexor) in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma (MM) after one prior therapy. The reimbursement has taken effect on March 1, 2026. This marks the second XPOVIO^® indication to be approved for reimbursement in South Korea.

As Antengene continues to expand its footprint across the Asia Pacific region, the Company remains committed to improving patient access to its innovative therapies. To date, XPOVIO^® has been approved in South Korea for three indications in MM and diffuse large B-cell lymphoma (DLBCL), both major hematological malignancies. Two of these indications have been approved for reimbursement, including XPOVIO^® in combination with dexamethasone for the treatment of adult patients with relapsed or refractory MM (R/R MM) who have received at least four prior therapies, as well as the newly reimbursed indication. With expanded reimbursement coverage, XPOVIO^® is expected to benefit a broader patient population and further contribute to the management of hematological malignancies in South Korea.

With a novel mechanism of action, XPOVIO^® is the world’s first approved orally-available, selective XPO1 inhibitor. XPOVIO^® has already been approved in ten countries and regions in APAC, and has been included in the national insurance schemes in five of these markets (the mainland of China, Taiwan market, Australia, Singapore and South Korea). Moving forward, Antengene will continue to pursue broader access for XPOVIO^® across APAC markets.

About Antengene

Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK) is a global, R&D-driven, commercial-stage biotech company focused on developing first-in-class/best-in-class therapeutics for diseases with significant unmet medical needs. Its pipeline spans from preclinical to commercial stages and includes several in-house discovered programs, including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 × 4-1BB bispecific antibody), and ATG-042 (oral PRMT5-MTA inhibitor).

Antengene has also developed AnTenGager™, a proprietary T cell engager 2.0 platform featuring “2+1” bivalent binding for low expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS) and enhance efficacy. These characteristics support the platform’s broad applicability across autoimmune disease, solid tumors and hematological malignancies, with programs targeting CD19 x CD3 (ATG-201 for B cell-related autoimmune diseases), CDH6 x CD3 (ATG-106 for ovarian cancer and kidney cancer), ALPPL2 x CD3 (ATG-112 for gynecologic tumors and non-small cell lung cancer), LY6G6D x CD3 (ATG-110 for microsatellite-stable colorectal cancer), GPRC5D x CD3 (ATG-021 for multiple myeloma), LILRB4 x CD3 (ATG-102 for acute myeloid leukemia and chronic myelomonocytic leukemia) and FLT3 x CD3 (ATG-107 for acute myeloid leukemia).

To date, Antengene has obtained 32 investigational new drug (IND) approvals in the U.S. and Asia, and obtained new drug application (NDA) approvals in 10 Asia Pacific markets. Its lead commercial asset, XPOVIO^® (selinexor), is approved in the Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia, Thailand, Indonesia and Australia, and has been included in the national insurance schemes in five of these markets (Mainland of China, Taiwan China, Australia, South Korea and Singapore).

Forward-looking statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company’s Annual Report for the year ended December 31, 2024, and the documents subsequently submitted to the Hong Kong Stock Exchange.

For more information, please contact:

Investor Contacts: 
Donald Lung
E-mail: donald.lung@antengene.com  

BD Contacts:
Ariel Guo
E-mail: ariel.guo@antengene.com

SINGAPORE, March 2, 2026 /PRNewswire/ — Toku Ltd. (“Toku“, “投酷有限公司” or the “Company”, and together with its subsidiaries, the “Group”), a Singapore-incorporated AI-powered customer experience (CX) platform, is pleased to announce its financial results for the full year ended 31 December 2025 (“FY2025”).

Commenting on the FY2025 results, Thomas Laboulle, Founder and Chief Executive Officer said, “Completing our IPO while operating with a streamlined team and disciplined capital allocation made this undoubtedly a challenging year. I am incredibly proud that we still delivered 9.3% revenue growth, our strongest Adjusted EBITDA to date, new market expansion, and the early monetisation of our Core AI Suite. These results reflect the resilient growth engine we have built. Looking ahead, our focus turns to scaling AI-driven capabilities, deepening our presence across APAC, and beyond, and strengthening the partnerships that will power our next phase of growth.”

Christian Wong, Chief Financial Officer, added: “The financial results for FY2025 demonstrate that our team can simultaneously manage a complex listing process and deliver meaningful operational improvement. Adjusted EBITDA improved 17.8% to its strongest full-year result, with underlying operating expenses declining 7.5% despite continued geographic expansion. The IPO has been transformative for our capital structure: all convertible instruments have been settled, shareholder loans repaid, and our highest-cost debt facility is scheduled for early retirement in April. With these transitional items behind us, the Group enters FY2026 in its strongest financial position since inception, well placed to convert revenue growth into progressive margin improvement.”

Financial Review

In FY2025, the Group revenue increased 9.3% from US$31.8 million in FY2024 to US$34.8 million in FY2025, extending its multi-year growth trajectory. The increase was primarily driven by higher Usage revenue and continued platform adoption across the Group’s expanding geographic footprint.

Usage revenue, the Group’s largest revenue stream, increased by 21.0% from US$19.8 million to US$23.9 million in FY2025, accounting for 68.8% of total revenue (FY2024: 62.2%). The growth was supported by the full-year contribution from its Latin American operations, higher traffic volumes from existing APAC customers, and early contributions from new deployments. During FY2025, the Group commenced monetisation of its AI-powered capabilities, with the Core AI Suite gaining customer adoption. While the associated revenue contribution was not yet material, AI-driven usage is expected to contribute progressively as deployments scale from FY2026 onwards.

Subscriptions and Licensing revenue edged higher to US$5.6 million, providing a recurring contracted base. Professional Services revenue declined 25.6% to US$2.4 million (FY2024: US$3.3 million), reflecting the Company’s reduced delivery capacity following workforce optimisation initiatives in 2H2024, as well as delayed project commencements. Despite a smaller workforce, resource utilisation improved year-on-year, underscoring stronger operational discipline and improved efficiency within a streamlined structure. With delivery capacity stabilising and pipeline conversions underway, the segment is positioned for recovery, further supported by the expanding channel partner programme. Maintenance and Support revenue decreased 12.2% to US$2.6 million in the same financial period, primarily due to the completion of certain legacy contracts. Recurring support requirements from new enterprise deployments in APAC, LATAM and the MENA regions, together with the expansion of its channel partner programme, are expected to underpin the Group’s medium-term growth across selected revenue streams. This momentum is reflected in recent developments, including a multi-market European enterprise agreement with a leading on-demand delivery platform.

Gross profit decreased 3.1% to US$8.4 million in FY2025 (FY2024: US$8.7 million), with gross profit margin declining from 27.4% to 24.3% for the fiscal year. The margin contraction was primarily due to a shift in revenue mix, as lower-margin Usage revenue expanded its share of total revenue from 62.2% in FY2024 to 68.8% in FY2025. This was compounded by reduced contributions from higher-margin Professional Services and Maintenance and Support revenue streams during the period.

The Group’s overall gross profit margin levels reflect its strategic positioning as a comprehensive enterprise platform operating across the entire customer experience value chain. While overall margins may be lower than those of pure software providers, this is consistent with the Group’s integrated platform strategy of combining connectivity infrastructure with higher-margin software and services offerings. This approach supports customer retention and provides a foundation for margin improvement as scale increases and higher-margin offerings expand.

The reported EBITDA loss widened to US$8.5 million in FY2025 (FY2024: US$4.4 million), reflecting the inclusion of approximately US$5.3 million in non-cash and non-recurring items, primarily listing costs and accelerated share-based expenses. Excluding these IPO-related items, Adjusted EBITDA improved to a loss of US$3.3 million in FY2025 from a loss of US$4.0 million in FY2024, marking the Group’s strongest full-year EBITDA performance to date. The adjusted EBITDA margin improved by 3.2 percentage points from (12.6%) in FY2024 to (9.4%) in FY2025, driven by revenue growth and operating expense discipline, reflecting improving operating leverage as the Group scales.

Interest expense increased to US$0.8 million due to higher average borrowings during the year. The Group’s venture debt facility with IRIS Fund LP is scheduled for early repayment on 9 April 2026, which is expected to eliminate the associated interest costs. Following the IPO, all convertible instruments have been converted into equity and shareholder loans repaid, resulting in a simplified capital structure.

As such, net loss for FY2025 was US$9.1 million (FY2024: US$5.3 million), largely attributable to approximately US$4.9 million of non-cash and non-recurring items recognised predominantly in Q4 2025 in connection with the IPO. These comprised fair-value adjustments on pre-IPO redeemable convertible loans, listing-related professional and regulatory fees, and accelerated share-based payment charges arising from the settlement of the employee share option plan.

Excluding these non-recurring and non-cash items, as well as the non-recurring deferred tax credit recognised during the year, Adjusted Net Loss improved by 8.5% to US$4.2 million in FY2025 (FY2024: US$4.6 million). The Adjusted Net Loss margin improved from (14.5%) to (12.1%) in the respective periods, reflecting revenue growth and operating cost discipline.

Business Outlook

The Group enters FY2026 with a simplified capital structure, improving operational momentum, and several catalysts for growth, particularly across APAC and the Middle East and North Africa (MENA) markets. Management expects AI-driven usage to contribute progressively to revenue as the Core AI Suite and Agentic AI programme move into broader production deployment. The expanding channel partner programme is anticipated to accelerate Subscriptions and Licensing growth, while Professional Services is positioned for recovery as delivery capacity stabilises and partner-delivered engagements complement direct delivery.

Margin improvement remains a key management priority. The revenue mix is expected to shift gradually towards higher-margin software and AI-enhanced services, while the transition to a channel partner-led distribution model is designed to enable the Group to scale without proportional cost increases. The Group anticipates higher recurring compliance and marketing costs in FY2026 as a newly listed entity, though these are expected to be progressively absorbed as operating leverage builds.

With pre-IPO transitional items behind it and its highest-cost borrowing facility scheduled for early retirement, the Group is well positioned to pursue its medium-term profitability objective while continuing to expand across APAC, LATAM, and the MENA region.

Over the next 12 months, the Group’s performance may be affected by factors such as the pace of AI adoption and monetisation at scale, the expansion of the channel partner programme, and the execution of potential strategic acquisitions. This may also be further influenced by competitive pricing dynamics in traditional connectivity services, macroeconomic conditions in key markets the Group operates in, and foreign exchange movements.

—END—

About Toku

Headquartered in Singapore, Toku Ltd. (“Toku“) is a cloud-native, AI-powered customer experience platform purpose-built for enterprises operating in complex, multi-market environments. With deep roots in the APAC region and an expanding global footprint, Toku’s modular 360° CX Platform orchestrates customer interactions across voice, chat, email and digital channels while managing regulatory, linguistic and infrastructure complexity at scale.

Built on end-to-end ownership of its technology stack, from carrier-grade connectivity to AI applications, Toku delivers enterprise-grade security, reliability and deployment flexibility across commercial cloud, private data centres and hybrid environments. Its AI capabilities include transcription, summarisation, sentiment analysis, conversation analytics and governed virtual agents, designed to integrate seamlessly with enterprise systems and customer data.

Trusted by leading enterprises and public-sector organisations, Toku helps organisations streamline operations, scale customer engagement and deliver consistent experiences across fragmented markets.

For more information about Toku, visit toku.co

Toku Ltd. (the “Company“) was listed on Catalist of the Singapore Exchange Securities Trading Limited (the “Exchange“) on 22 January 2026. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte. Ltd. (the “Sponsor“).

This press release has been reviewed by the Sponsor. It has not been examined or approved by the Exchange and the Exchange assumes no responsibility for the contents of this press release, including the correctness of any of the statements or opinions made or reports contained in this press release. 

The contact person for the Sponsor is Ms. Ng Shi Qing, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg.

The Future of Prostate Imaging: What do physicians want?

MELBOURNE, Australia and INDIANAPOLIS, March 2, 2026 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) invites investors to join a webinar with key opinion leaders to discuss a physician’s perspective on innovations in PSMA-PET/CT imaging for prostate cancer.

Speakers:

• Rodney Hicks, MD, Professor of Medicine at the University of Melbourne and Monash University; Founder, Executive Chairman and Chief Medical Officer at the Melbourne Theranostic Innovation Centre (MTIC);  
• Paul Yonover, MD, FACS, Chief Data Officer and Director of Clinical Navigation at UroPartners, a division of The Specialty Alliance; Chief of Urology at Ascension Saint Joseph Hospital, Chicago; and
• Darren Patti, PharmD, Telix Group Chief Operating Officer.

The webinar will be moderated by David N. Cade, MD, Telix Group Chief Medical Officer.

The webinar will be held on:

EST: Wednesday March 4, 2026, 5:30 p.m.
AEDT: Thursday March 5, 2026, 9:30 a.m.
The event will run for approximately one hour.

Participants can register for the webcast at the following link: https://edge.media-server.com/mmc/p/n87mam6r

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook.

Legal Notices

Cautionary Statement Regarding Forward-Looking Statements. 

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification.  To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, including the planned NDA resubmission for TLX101-Px and the planned BLA resubmission for TLX250-Px, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.

©2026 Telix Pharmaceuticals Limited. All rights reserved.